Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis
Recruiting now Phase 2 NCT06913647
Run by McGill University Health Centre/Research Institute of the McGill University Health Centre · for 18 and older · All sexes
What this study is about
This is a phase II, proof-of-concept, placebo-controlled, double-blind, cross-over randomized clinical trial, assessing the effect of canagliflozin on peritoneal membrane function in patients on PD. The primary aim of this trial is to determine the short-term effects of canagliflozin, an SGLT-2 inhibitor, on glucose absorption by the peritoneal membrane and on ultrafiltration, as assessed by a standardized peritoneal equilibrium test. The secondary aims are to determine the effect of canagliflozin on solute clearance and on effluent biomarkers of inflammation, angiogenesis, and fibrosis at 26 weeks. We hypothesize that canagliflozin will prevent glucose absorption by the peritoneal membrane, as compared with placebo, and will attenuate the development of inflammation, angiogenesis, and fibrosis of the peritoneal membrane, as assessed by relevant biomarkers in the dialysate.
Who can join (things the study team will check)
✅ You may be able to join if…
- Adult patients with kidney failure on PD (both incident and prevalent) who are on a stable prescription of dextrose-based solutions for at least 3 months.
- Only high or high-average transporters, as classified by PET, will be included.
🚫 You may not be able to join if…
- History of euglycemic ketoacidosis
- Known hypersensitivity to canagliflozin
- Active peritonitis or tunnel infection
- Kidney transplant scheduled in the next 6 months
- Severe liver cirrhosis (Child-Pugh class C stage)
- Recurrent severe genital or urine infections
- Patients receiving digoxin, phenobarbital, phenytoin, rifampin, or ritonavir if these agents cannot be safely discontinued
- Pregnancy or breastfeeding
Where this trial is running
- Research Institute-McGill University Health Center, Montreal, Quebec, Canada
Who to contact
Efrosyne Tsirella · 514-934-1934 · efrosyne.tsirella@muhc.mcgill.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06913647.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.